Production Initiated for VAL001
Respiratorius announces that the development of the novel formulation of VAL001 has been completed and production initiated.characteristics of sodium valproate contained in a pellet formulation. This tailored release profile will be evaluated in a pharmacokinetic (PK) phase I study in healthy subjects. The submission processes for initiating the PK study are in progress, with the ethical committee submission already completed. Positive evaluation and approvals from all necessary regulatory bodies for study start are expected before end of 2021. In parallel with the product related